What AI Actually Fixes in Remote Care, and What It Quietly Fails At

Remote care is where artificial intelligence has produced some of its most concrete, reproducible gains, but the gains cluster in specific places, not everywhere the marketing suggests. Chronic disease monitoring has meta-analytic evidence behind it. Image-based screening extends specialist judgment across distance with regulator-grade accuracy. Ambient documentation is making virtual visits function better for clinicians. Symptom-checker triage, the most visible AI-in-remote-care product to the public, has not gotten more accurate in five years of independent testing. And in resource-constrained health systems, the binding constraint on most of this is rarely the algorithm. It is the network, the power supply, and the financing model underneath it.

Remote monitoring has the strongest evidence base, with real caveats

Remote patient monitoring, digital transmission of vital signs and symptoms from a patient's home to a care team, is the most rigorously tested category of remote care technology, and increasingly the data streams it produces are triaged and flagged by AI models rather than reviewed manually.

A 2025 meta-analysis in the European Journal of Heart Failure pooled 41 randomized controlled trials covering 16,312 heart failure patients and found remote monitoring associated with 19 percent lower odds of mortality (pooled odds ratio 0.81, 95% CI 0.69 to 0.95) and 22 percent lower odds of a first heart failure hospitalization (pooled OR 0.78, 95% CI 0.70 to 0.87), compared with usual care (De Lathauwer et al., 2025). This is strong evidence, a meta-analysis of RCTs. The same analysis found the effect was concentrated in programs that included a self-management module, an education module, or video contact with the care team, which matters for how these systems should be designed, not just whether they exist.

A broader systematic review across noncommunicable diseases, published in JMIR mHealth and uHealth, pooled 40 RCTs from 2017 to 2024 and found remote monitoring associated with a modest reduction in the proportion of patients hospitalized (risk ratio 0.86, 95% CI 0.77 to 0.95), a finding the authors themselves graded as low-certainty evidence under GRADE, and no meaningful change in outpatient or emergency visits (Smedslund et al., 2025). We flag this honestly rather than round it up. Most of this RCT evidence tests remote data collection generally, not AI specifically. AI's role has mostly been to convert that data into a smaller number of actionable alerts, which is a workflow claim more than an outcomes claim, and one that has not yet been isolated in its own trials.

AI symptom checkers have not gotten more accurate, they have gotten more confident

Public-facing AI triage tools are the most heavily marketed application of AI to remote care and the one with the weakest track record. A five-year follow-up audit published in the Journal of Medical Internet Research tested 22 symptom checker apps and found median triage accuracy of 55.8 percent in 2020, essentially unchanged from 59.1 percent in 2015, with the tested apps missing more than 40 percent of true emergencies and no app outperforming laypersons on both the decision to seek emergency care and the decision that self-care was sufficient (Schmieding et al., 2022). This is limited evidence by design, a single audit study, but it is a large, repeated one, and it directly contradicts the assumption that these tools have quietly gotten better.

A November 2025 vignette study comparing general-purpose AI chatbots against the UK's NHS 111 symptom checker across NICE-guideline cases reached a similar conclusion: general-purpose AI showed potential as an adjunct to existing triage lines but was not yet reliable enough for standalone use, with inconsistent over-triage and under-triage across emergency and non-emergency vignettes (Brown et al., 2025). Emerging evidence, one study, but consistent with the audit above. The honest summary is that AI triage remains a decision-support layer that requires human backstop, not a substitute for it, and any remote care product that markets it otherwise is overstating what the tools do.

Image-based screening is where AI most reliably extends a scarce specialist

Screening conditions that depend on trained visual interpretation, chiefly diabetic retinopathy, is where AI has the strongest regulatory and clinical track record in remote care. A 2025 systematic review and meta-analysis in npj Digital Medicine covering regulator-approved deep learning systems for diabetic retinopathy found these tools correctly identified approximately 93 percent of referable cases while correctly excluding 87 to 92 percent of non-cases, matching or exceeding expert human graders (strong evidence, a meta-analysis of cleared, regulator-approved systems) (npj Digital Medicine, 2025). Several of the underlying systems hold US FDA clearance or CE marking, though clearance in the United States or Europe does not imply approval in Uganda or elsewhere in the region, and jurisdictional status has to be checked separately in each market.

The same review flagged a real gap worth stating plainly: only one included study came from a low-income country. A separate real-world validation in Dominica, a middle-income setting, found smartphone-based AI screening performed with 81.4 percent sensitivity and 91.5 percent specificity against a specialist grader (moderate evidence, one prospective validation study) (Mathenge et al., 2023), and a systematic review focused specifically on low- and middle-income countries found high diagnostic accuracy where it has been tested, alongside a scarcity of studies overall and one report of meaningful cost savings per patient screened, a vendor-adjacent figure from a single study that we flag rather than generalize (PMC, 2025).

Accuracy is not the same as successful deployment. A widely cited case study of Google Health's retinopathy algorithm in Thailand found that despite strong laboratory accuracy, real-world performance was undermined by low internet speeds, screening rooms unsuited to image capture, and workflows the tool was not designed around, a cautionary example of what happens when a validated model meets an unvalidated environment (Beede et al., 2020, as analyzed in Sambasivan & Veeraraghavan, 2020). The lesson generalizes beyond ophthalmology: accurate models still fail without infrastructure and workflow design built around the setting they will run in.

Ambient documentation is changing how virtual visits feel, not yet what they achieve

Ambient AI scribes, which listen to a clinical encounter and draft the note, are increasingly built into telehealth platforms specifically because virtual visits are prone to fragmented documentation when a clinician is managing both a screen and a conversation. A randomized trial of ambient AI scribes found physicians rated the tools easy to use and reported being able to engage more directly with patients during the visit, a mechanism distinct from raw time savings (moderate evidence, single RCT) (PMC, 2025). A rapid review synthesizing real-world evidence across digital scribes found consistent reductions in self-reported documentation time and improved clinician engagement, but no change in standardized burnout scores and no change in billing-based productivity metrics, evidence that is genuinely mixed rather than uniformly positive (PMC, 2025). As one recent analysis in npj Digital Medicine put it plainly, studies of ambient scribes have so far focused on efficiency and clinician experience, with no evidence yet of improved clinical or patient-centered outcomes, and it noted a specific concern for resource-constrained settings: many ambient scribe products depend on continuous cloud connectivity, which is precisely the resource that is least reliable where remote care is needed most (npj Digital Medicine, 2026).

In resource-constrained systems, infrastructure is the bottleneck AI cannot route around

The most informative large-scale evidence on remote care in a low-resource setting is not, strictly speaking, about AI at all. Babyl, Rwanda's national telemedicine platform, ran from 2019 to September 2023 and recorded 3.9 million consultations, with triage nurses and senior nurses together managing nearly 70 percent of cases under physician oversight, exceeding the World Health Organization's target of 50 percent nurse-led primary care management in resource-limited settings. An interrupted time series analysis of national health records found the platform's introduction was associated with an immediate drop in facility-based visits for common conditions, including a roughly 75 percent reduction in respiratory infection visits at facilities, and found that utilization patterns reversed toward facility-based care after the service was discontinued (moderate evidence, a large-scale observational interrupted time series) (Rubuga et al., 2026). The result illustrates what well-run remote care infrastructure can do at national scale, and the reversal after discontinuation illustrates how fragile that gain is without sustained financing.

Systematic reviews of telemedicine adoption across low- and middle-income countries consistently name the same barriers regardless of country: unreliable internet and electricity, unclear regulatory frameworks for cross-border or remote consultation, low digital literacy among both patients and providers, and financing models that depend on donor support rather than durable local budgets (Dhyani et al., 2023; Discover Public Health, 2026). None of these barriers are solved by a better model. They are solved by design choices, offline-capable tools, lightweight data transmission, task-shifted workflows that do not assume constant specialist availability, and financing that survives past a pilot's initial grant cycle.

Where Curely's Remote Care and Telemedicine solution fits

Curely's Remote Care and Telemedicine solution is built around that constraint rather than around it being someone else's problem to solve later. It is designed to support task-shifted triage, where trained nurses or clinical officers handle the first assessment with AI-assisted decision support and physician oversight reserved for cases that need it, in the pattern the Rwanda evidence above suggests actually works at scale. It is designed for intermittent and low-bandwidth connectivity rather than assuming constant broadband, since that assumption is where several of the deployment failures cited above originated. And it is built as part of Curely's broader agent ecosystem, so that a remote consultation can draw on the same clinical decision support and documentation tools used in-facility, rather than operating as a disconnected add-on product.

We describe this as design intent rather than proven outcomes, because we have not yet published population-level results of the kind the Rwanda study or the heart failure meta-analysis represent, and a credible piece of writing does not borrow evidence it has not earned. The honest claim is narrower and, we think, more useful to a hospital administrator evaluating the option: the architecture is built around the specific failure modes the evidence above documents, low connectivity, workforce scarcity, and the gap between laboratory accuracy and real-world deployment, rather than around a generic assumption that intelligence alone closes access gaps.

The takeaway

AI is improving remote care in specific, testable ways: chronic disease monitoring with meta-analytic support, image-based screening with regulator-grade accuracy where the infrastructure exists to support it, and documentation tools that make virtual visits function better for the clinician running them. It is not yet reliably improving public-facing symptom triage, and it cannot substitute for the network, power, financing, and workforce planning that determine whether any of this reaches a patient outside a well-resourced hospital. For a health system deciding where to invest, the evidence points toward monitoring and screening first, triage tools treated with real skepticism, and infrastructure treated as the actual project, not the afterthought.